{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:58Z","timestamp":1793973598445,"version":"4.8.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82302007"],"award-info":[{"award-number":["82302007"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010915","name":"American Society of Transplant Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005160","name":"American Society of Transplantation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.critrevonc.2025.104730","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T11:07:53Z","timestamp":1744628873000},"page":"104730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"211","author":[{"given":"Qibin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr. Probl. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker","year":"2024","journal-title":"JBI Evid. Synth."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study","volume":"17","author":"Bestvina","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib4","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104730_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","volume":"24","author":"Butterfield","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00262-024-03872-6","article-title":"Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma","volume":"74","author":"Cao","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2025.104730_bib7","article-title":"Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: a prospective, single-arm, single-center clinical study","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41416-024-02684-w","article-title":"The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications","volume":"131","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104730_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104730_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000533425","article-title":"Survival outcome analysis of stereotactic body radiotherapy and immunotherapy (SBRT-IO) versus SBRT-alone in unresectable hepatocellular carcinoma (HCC)","volume":"13","author":"Chiang","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.critrevonc.2025.104730_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100702","article-title":"New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma","volume":"51","author":"Dal Bo","year":"2020","journal-title":"Drug Resist Update"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104730_bib13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.hpb.2024.02.003","article-title":"Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"26","author":"Dawood","year":"2024","journal-title":"HPB (Oxford)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership","volume":"63","author":"Demaria","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104730_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CMAR.S391529","article-title":"Safety and efficacy of concurrent or sequential radiotherapy plus (PD-1) inhibitors in oligometastatic esophageal cancer","volume":"15","author":"Duan","year":"2023","journal-title":"Cancer Manag Res."},{"issue":"543","key":"10.1016\/j.critrevonc.2025.104730_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1259\/0007-1285-46-543-220","article-title":"Abscopal effect of radiation in papillary adenocarcinoma","volume":"46","author":"Ehlers","year":"1973","journal-title":"Br. J. Radiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104730_bib17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104730_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104730_bib19","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/cco-23-140","article-title":"Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review","volume":"13","author":"Hall","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104730_bib21","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/JHC.S459683","article-title":"A novel nomogram to predict prognosis of advanced hepatocellular carcinoma treated with intensity-modulated radiotherapy plus anti-PD1","volume":"11","author":"He","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104730_bib23","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1158\/1078-0432.CCR-22-2592","article-title":"Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus","volume":"29","author":"Hu","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104730_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065849","article-title":"Local liver irradiation concurrently versus sequentially with cabozantinib on the pharmacokinetics and biodistribution in rats","volume":"24","author":"Huang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12885-023-10960-w","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104730_bib26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jclinepi.2014.03.003","article-title":"In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias","volume":"67","author":"Hunter","year":"2014","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.04.023","article-title":"The promise of combining radiation therapy with immunotherapy","volume":"108","author":"Jagodinsky","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12885-024-12154-4","article-title":"Carbon-ion radiotherapy for hepatocellular carcinoma with major vascular invasion: a retrospective cohort study","volume":"24","author":"Kaneko","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104730_bib29","article-title":"Modeling the synergistic impact of yttrium 90 radioembolization and immune checkpoint inhibitors on hepatocellular carcinoma","volume":"11","author":"Kang","year":"2024","journal-title":"Bioengineering (Basel)"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104730_bib30","doi-asserted-by":"crossref","first-page":"41242","DOI":"10.18632\/oncotarget.17168","article-title":"Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104730_bib31","article-title":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: a phase II study","volume":"6","author":"Kim","year":"2024","journal-title":"JHEP Rep."},{"issue":"10474","key":"10.1016\/j.critrevonc.2025.104730_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104730_bib33","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104730_bib34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3350\/cmh.2023.0274","article-title":"Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104730_bib35","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","article-title":"A phase I\/IIa trial of yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104730_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13014-022-02075-6","article-title":"Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study","volume":"17","author":"Li","year":"2022","journal-title":"Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib38","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","article-title":"Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104730_bib39","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.critrevonc.2025.104730_bib40","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2147\/JHC.S432542","article-title":"Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: real-world data from a tertiary centre","volume":"10","author":"Li","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib41","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.21037\/tcr-23-1333","article-title":"Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases","volume":"13","author":"Liang","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104730_bib42","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib43","article-title":"Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib45","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104730_bib46","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104730_bib47","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol."},{"issue":"305","key":"10.1016\/j.critrevonc.2025.104730_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation\u2014radiobiology or medicine?","volume":"26","author":"Mole","year":"2014","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.critrevonc.2025.104730_bib49","series-title":"JBI Manual for Evidence Synthesis","article-title":"Systematic reviews of etiology and risk (2020)","author":"Moola","year":"2024"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104730_bib50","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch. Public Health"},{"key":"10.1016\/j.critrevonc.2025.104730_bib52","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7854","key":"10.1016\/j.critrevonc.2025.104730_bib53","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104730_bib54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10408","key":"10.1016\/j.critrevonc.2025.104730_bib55","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104730_bib56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10474","key":"10.1016\/j.critrevonc.2025.104730_bib57","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104730_bib58","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","article-title":"Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO","volume":"23","author":"Scoccianti","year":"2021","journal-title":"Neuro Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104730_bib59","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s43018-022-00467-x","article-title":"Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade","volume":"3","author":"Spurr","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104730_bib60","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104730_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.873830","article-title":"PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma","volume":"12","author":"Su","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104730_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972503","article-title":"PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: a propensity score matching study","volume":"13","author":"Su","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib63","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13014-021-01778-6","article-title":"Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study","volume":"16","author":"Su","year":"2021","journal-title":"Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib64","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1186\/s12885-024-12940-0","article-title":"Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study","volume":"24","author":"Sun","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104730_bib65","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104730_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254158","article-title":"Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching","volume":"14","author":"Tang","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104730_bib67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030386","article-title":"Effect of synchronous versus sequential regimens on the pharmacokinetics and biodistribution of regorafenib with irradiation","volume":"13","author":"Tsai","year":"2021","journal-title":"Pharmaceutics"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2025.104730_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4110","article-title":"Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study","volume":"42","author":"Vogel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104730_bib70","article-title":"Stereotactic body radiotherapy combined with lenvatinib with or without PD-1 inhibitors as initial treatment for unresectable hepatocellular carcinoma","author":"Wang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104730_bib71","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1097\/JS9.0000000000000652","article-title":"Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"109","author":"Wang","year":"2023","journal-title":"Int. J. Surg."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104730_bib72","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2025.104730_bib73","article-title":"Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104730_bib74","article-title":"Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2025.104730_bib75","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9024","article-title":"Time from stereotactic body radiotherapy to immunotherapy as a predictor for outcome in metastatic non small cell lung cancer","volume":"37","author":"Wegner","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104730_bib76","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104730_bib77","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib79","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-025-56537-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2025.104730_bib80","article-title":"SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: a randomized phase 3 trial","volume":"42","author":"Xu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104730_bib81","article-title":"The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104730_bib82","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2468-1253(23)00454-5","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study","volume":"9","author":"Yau","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib83","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104730_bib84","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","article-title":"A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma","volume":"29","author":"Yu","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104730_bib85","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5582\/bst.2015.01089","article-title":"Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Biosci. Trends"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104730_bib86","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104730_bib87","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000528698","article-title":"Adverse events of immune checkpoint inhibitor-based therapies for unresectable hepatocellular carcinoma in prospective clinical trials: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.critrevonc.2025.104730_bib88","article-title":"Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study","author":"Zhu","year":"2024","journal-title":"Hepatology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:28:14Z","timestamp":1762352894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":88,"alternative-id":["S1040842825001180"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104730","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104730"}}